Pfiz­er and Val­neva's Ly­me dis­ease bet rolls on to PhI­II as more fi­nanc­ing flows their way

Pfiz­er’s core fo­cus on vac­cine de­vel­op­ment ex­tends well be­yond the Covid-19 fran­chise. Their bet on a Ly­me dis­ease can­di­date out of Val­ne­va is con­tin­u­ing to pump out pos­i­tive da­ta, point­ing the part­ners to­ward a Phase III tri­al. And the French biotech is adding an ad­di­tion­al $40 mil­lion in fresh debt fi­nanc­ing from a pair of ma­jor play­ers in the in­dus­try to help pay the freight for new de­vel­op­ment work.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER